Opioid-mediated muscle afferents inhibit central motor drive and limit peripheral muscle fatigue development in humans.
about
Fatigue is a Brain-Derived Emotion that Regulates the Exercise Behavior to Ensure the Protection of Whole Body HomeostasisNeurophysiological Determinants of Theoretical Concepts and Mechanisms Involved in PacingNutritional interventions to augment resistance training-induced skeletal muscle hypertrophySignificance of Group III and IV muscle afferents for the endurance exercising humanNeuromuscular consequences of an extreme mountain ultra-marathonAre There Critical Fatigue Thresholds? Aggregated vs. Individual Data.Group III/IV muscle afferents impair limb blood in patients with chronic heart failure.An official American Thoracic Society/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease.Impact of pulmonary system limitations on locomotor muscle fatigue in patients with COPD.The role of active muscle mass in determining the magnitude of peripheral fatigue during dynamic exercise.Factors affecting the regulation of pacing: current perspectivesGroup III and IV muscle afferents contribute to ventilatory and cardiovascular response to rhythmic exercise in humans.Psychophysical stress increases the expression of phospho-CREB, Fos protein and neurokinin-1 receptors in superficial laminae of trigeminal subnucleus caudalis in female rats.Disparity in regional and systemic circulatory capacities: do they affect the regulation of the circulation?Interaction of central and peripheral factors during repeated sprints at different levels of arterial O2 saturation.Prior heat stress effects fatigue recovery of the elbow flexor muscles.Myoelectrical manifestation of fatigue less prominent in patients with cancer related fatigueAutonomic responses to exercise: group III/IV muscle afferents and fatigue.Humans In Hypoxia: A Conspiracy Of Maladaptation?!Five-Kilometers Time Trial: Preliminary Validation of a Short Test for Cycling Performance Evaluation.Intrathecal fentanyl blockade of afferent neural feedback from skeletal muscle during exercise in heart failure patients: Influence on circulatory power and pulmonary vascular capacitanceExploring the performance reserve: Effect of different magnitudes of power output deception on 4,000 m cycling time-trial performance.Improved Ventilatory Efficiency with Locomotor Muscle Afferent Inhibition is Strongly Associated with Leg Composition in Heart FailureAging alters muscle reflex control of autonomic cardiovascular responses to rhythmic contractions in humans.Muscle mass and peripheral fatigue: a potential role for afferent feedback?Central and Peripheral Fatigue During Resistance Exercise - A Critical Review.Cortical and segmental excitability during fatiguing contractions of the soleus muscle in humansControl and sensation of breathing during cycling exercise in hypoxia under naloxone: a randomised controlled crossover trial.Peripheral fatigue limits endurance exercise via a sensory feedback-mediated reduction in spinal motoneuronal output.AltitudeOmics: on the consequences of high-altitude acclimatization for the development of fatigue during locomotor exercise in humans.Ascorbate infusion increases skeletal muscle fatigue resistance in patients with chronic obstructive pulmonary disease.Mechanism of augmented exercise hyperpnea in chronic heart failure and dead space loading.EFFECT OF DIFFERENT FOAM ROLLING VOLUMES ON KNEE EXTENSION FATIGUE.No Critical Peripheral Fatigue Threshold during Intermittent Isometric Time to Task Failure Test with the Knee Extensors.Group III/IV locomotor muscle afferents alter motor cortical and corticospinal excitability and promote central fatigue during cycling exercise.Pulmonary system limitations to endurance exercise performance in humansExogenously applied muscle metabolites synergistically evoke sensations of muscle fatigue and pain in human subjects.No Influence of Transcutaneous Electrical Nerve Stimulation on Exercise-Induced Pain and 5-Km Cycling Time-Trial Performance.Oxidative stress and COPD: the effect of oral antioxidants on skeletal muscle fatigue.MAXIMUM REPETITION PERFORMANCE AFTER DIFFERENT ANTAGONIST FOAM ROLLING VOLUMES IN THE INTER-SET REST PERIOD.
P2860
Q21129258-95E14C24-B98D-4E84-AADB-D3911CB3CA90Q22252564-06EC732F-26EE-48AE-A9B5-F86E774A7669Q26782957-B0B9CDE3-0945-4786-B7DA-649AC49A43CBQ27012787-99A9DFB9-8BAD-4246-B8EA-63927086358AQ28477233-271F531B-7B0F-4FDC-AEBD-588AD6B6A430Q31130893-D3430D9F-AA09-4DC4-90A1-6E830889119BQ33822116-A375D618-B116-4355-910F-8C13871244DAQ33901722-80E5C625-EE73-476B-8362-995BD513A05FQ33994968-5EA77F52-DFA8-4E15-BA9F-F930F38A5269Q34158019-EF65C29E-E2A1-45A3-BBFE-20236E91022FQ34166959-2764B0D5-D37F-4AE6-AED3-4B484B86E645Q34236432-797EFFD3-D3D3-4088-9DE8-162CD99FAF52Q34258815-7E130EB9-8F5D-402A-BF1F-D4CACCA50541Q34447030-54DF8DD1-B5FE-4DAE-9E40-38574C60CC8DQ35025426-4721A916-650F-45BD-8758-A232B500E842Q35051354-CB7A58BD-65FE-4390-9D02-28FF74E08280Q35082550-5200C943-FA71-46BF-A4C9-F4187C9762B6Q35108132-3D82EEBB-7CF2-4688-80A8-45FD73650D6FQ35817898-D8B9BF9E-B3B6-4D24-8C9D-2B2996F8C0CEQ36123818-AEE95E5E-589D-401D-A504-FBCA7F594E5CQ36157352-A87E37DC-4707-4F10-9B23-E021BCF994D8Q36302287-D2F095C9-AAE7-48B0-BF87-301B2D5A4F2CQ36307483-570F7E7C-F8E8-46CA-8D49-A084AAA2051EQ36339455-EE806EE7-1928-44D7-8C07-7F06223452BEQ36360680-1CF9D16F-A7A5-4128-A568-C16175169AB9Q36490942-1375020D-EFA9-44AC-9998-F192D1E61DBBQ36845224-609D843E-B1C9-443A-A99D-EF088A966D91Q37008454-F9A32E87-4B37-4BB2-9706-43476E84F9FEQ37094184-1FBA8F57-5299-4A57-B27D-0D85954D73FFQ37147199-91FE90E2-F2AF-4C7B-8AE4-EDF48698B601Q37346053-5CAAF266-9663-4F3C-8B79-3A2C99079BC5Q37467759-4A2C1412-705A-4F92-BC6B-B7B35DCB8865Q37507863-FF0DD5D7-7876-4A02-83C6-B2F38E05AFF2Q37512152-520BC6A0-8C0C-465B-8EE5-3D09A2913C09Q37589344-AF2DE337-8A01-43D5-9750-13E7EBBFC323Q37602794-B10E2FB1-69EF-4F13-8AE7-A8E7686FD56EQ37624800-D54B1ED9-1E09-4788-A776-331EB4EE28ADQ37627129-300EC250-9082-4F49-8C4B-9A1ECD0CB034Q37627485-5309C050-1A00-460D-82E0-8B778C8EC9CCQ37628164-C023CBCC-6E83-4EF4-8978-AC7A027D0E3B
P2860
Opioid-mediated muscle afferents inhibit central motor drive and limit peripheral muscle fatigue development in humans.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Opioid-mediated muscle afferen ...... fatigue development in humans.
@en
Opioid-mediated muscle afferen ...... fatigue development in humans.
@nl
type
label
Opioid-mediated muscle afferen ...... fatigue development in humans.
@en
Opioid-mediated muscle afferen ...... fatigue development in humans.
@nl
prefLabel
Opioid-mediated muscle afferen ...... fatigue development in humans.
@en
Opioid-mediated muscle afferen ...... fatigue development in humans.
@nl
P2093
P2860
P1476
Opioid-mediated muscle afferen ...... fatigue development in humans
@en
P2093
David F Pegelow
Jerome A Dempsey
Joshua J Sebranek
Lester T Proctor
P2860
P304
P356
10.1113/JPHYSIOL.2008.163303
P407
P50
P577
2008-11-17T00:00:00Z